Top Markets
Coin of the day
Bio-Path Holdings, Inc. Bio-Path Holdings, Inc.

Bio-Path Holdings, Inc.

BPTH
Peringkat dalam Saham #39843
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on... Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Harga Saham
$0.035
Terakhir disinkronkan: 2026-08-13
Kapitalisasi Pasar
$326.98K
Perubahan (1 hari)
-12.50%
Perubahan (1 tahun)
-74.55%
Negara
US
Perdagangan Bio-Path Holdings, Inc. (BPTH)

Kategori

Rasio P/B untuk Bio-Path Holdings, Inc. (BPTH)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari Bio-Path Holdings, Inc., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk Bio-Path Holdings, Inc. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.2613 -
US
6.3483 -
NL
- -
CH
- -
KR
3.634 -
BE